7182-38-9

Usage

Chemical Properties

Light Yellow Solid

Uses

GABA transaminase inhibitor.

InChI:InChI=1/C9H9ClO2/c10-6-5-9(12)7-1-3-8(11)4-2-7/h1-4,11H,5-6H2

Upstream product

• 625-36-5 2-chloropropionyl chloride 
• 108-95-2 phenol 
• 937-41-7 phenyl acrylate 

Downstream Products

• 53170-92-6 1-(4-hydroxyphenyl)-3'-oxopropyl-β-D-glucopyranose 
• 53170-93-7 3-hydroxy-1-(4-hydroxy phenyl)propan-1-one 
• 94913-28-7 N⁴-<2-(4-Hydroxy-benzoyl)-ethyl>-N¹-butylcarbamoyl-sulfanilamid 

Relevant academic research and scientific papers

Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one

Previously it was found that 4-hydroxybenzaldehyde is a competitive inhibitor of GABA transaminase. Here 3-chloro-1-(4-hydroxyphenyl)propan-1-one (9), a 4-hydroxybenzaldehyde analogue, was found to inactivate potently the enzyme in a time-dependent manner. α-Ketoglutarate prevented the enzyme from inactivation, suggesting that the inactivation occurs in its active site. Several experiments indicated that the inactivation is irreversible. This study provides a novel strategy for the design of more effective inhibitors.

Metabolically stable vanillin derivatives for the treatment of hypoxia

Vanillin derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided.

An investigation of structure‐activity relationships of azolylacryloyl derivatives yielded potent and long‐acting hemoglobin modulators for reversing erythrocyte sickling

Aromatic aldehydes that bind to sickle hemoglobin (HbS) to increase the protein oxygen affinity and/or directly inhibit HbS polymer formation to prevent the pathological hypoxia‐induced HbS polymerization and the subsequent erythrocyte sickling have for s

Synthesis and Evaluation of 2-Azetidinone and 1H-Pyrrole-2,5-dione Derivatives as Cholesterol Absorption Inhibitors for Reducing Inflammation Response and Oxidative Stress

Excess lipid accumulation can initiate the development and progression of atherosclerotic lesions, thus eventually leading to cardiovascular disease. Lipid-lowering medication therapy is one of the cornerstones of cardiovascular disease therapy. On the basis of the cholesterol absorption inhibitor ezetimibe, we successfully synthesized seven 2-azetidinone derivatives and eighteen 1H-pyrrole-2,5-dione derivatives. Most of the new compounds significantly inhibited cholesterol uptake in vitro. In addition, one of the most active inhibitors, 3-(4-fluorophenyl)-1-[(3S)-3-hydroxy-3-(4-hydroxyphenyl)propyl]-4-(4-hydroxyphenyl)-1H-pyrrole-2,5-dione (14q), showed no cytotoxicity in L02 and HEK293T cell lines. Further evaluation indicated that 14q inhibited considerably the amount of TNF-α, ROS, MDA, and LDH in vitro. Therefore, 14q might be a novel cholesterol absorption inhibitor.

SELECTIVE OCTAHYDRO-CYCLOPENTA[C] PYRROLE NEGATIVE MODULATORS OF NR2B

Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed. Such diseases include, without limitation, neurological dysfunction such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and seizure disorders; emotional disorders; depression; bipolar disorder; obsessive-compulsive disorder; and other anxiety disorders.

Preparative Bioorganic Chemistry, XVI. Synthesis of 3,4'-Dihydroxypropiophenone 3-&β-D-Glucopyranoside, a Constituent of Betula platyphylla var. japonica, by Enzymatic Transglucosylation

3,4'-Dihydroxypropiophenone 3-β-D-glucopyranoside (1a) has been synthesized, without having recourse to any protective group technology, by transglucosylation catalyzed by lactase from Kluyveromyces lactis. Key words: Antifeedant; Betula platyphylla; β-D-glucopyranoside; lactase; transglucosylation.